Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. The most frequently used first-line therapy remains generic phentermine, a drug that has been on the U.S. market for decades. However, since 2012, a number of novel branded drugs have entered the market with varying degrees of commercial success. Approved agents include Novo Nordisk’s Saxenda (liraglutide), Vivus’s Qsymia (phentermine / topiramate), Eisai’s Belviq (lorcaserin), and Nalpropion Pharmaceuticals’ Contrave (naltrexone / bupropion). This report provides important insights into how prescription weight-loss agents are used in the management of obesity and how practices are evolving.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Novo Nordisk, Vivus, Eisai, Nalpropion Pharmaceuticals
Key drugs: Saxenda, Qsymia, Contrave, Belviq, Xenical, phentermine